Polyreactivity and polyspecificity in therapeutic antibody development: risk factors for failure in preclinical and clinical development campaigns
-
- Orla Cunningham
- UltraHuman Eight Limited, C/o Kreston Reeves Llp, Kent, UK
-
- Martin Scott
- Department of Biopharm Discovery, GlaxoSmithKline Research & Development, Hertfordshire, UK
-
- Zhaohui Sunny Zhou
- Department of Chemistry and Chemical Biology, Barnett Institute for Chemical and Biological Analysis, Northeastern University, Boston, Massachusetts, USA
-
- William J.J. Finlay
- UltraHuman Eight Limited, C/o Kreston Reeves Llp, Kent, UK
収録刊行物
-
- mAbs
-
mAbs 13 (1), e1999195-, 2021-01-01
Informa UK Limited